Literature DB >> 7927788

Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin.

D M Roscoe1, S H Jung, I Benhar, L Pai, B K Lee, I Pastan.   

Abstract

NLysPE38 is a 38-kDa derivative of Pseudomonas exotoxin (PE) in which domain Ia (amino acids 1 to 252) and part of domain Ib (365 to 380) are deleted and an 11-amino-acid N-terminal peptide is added. LMB-1 is an immunotoxin in which the monoclonal antibody B3 is coupled to NLysPE38 near its N terminus. LMB-7 is a single-chain immunotoxin in which the Fv fragment of B3 is fused to PE38. To identify the antigenic regions of PE38, 12 polyclonal serum samples from monkeys immunized with the immunotoxins LMB-1 (six monkeys) and LMB-7 (six monkeys) were tested for their reactivity to a panel of 120 synthetic, overlapping peptides representing the amino acid sequence of NLysPE38. The antibody responses to peptides were similar among the 12 serum specimens, identifying several major immunodominant B-cell epitopes. Predominant reactivity was seen in six locations: amino acids 272 to 287, 341 to 359, 504 to 516, 540 to 564, and 573 to 591 and the C-terminal amino acids 591 to 613. The sera did not react with approximately 75% of the peptides. Furthermore, a computer-aided analysis was done to predict the immunologically relevant areas and revealed the same antigenic regions defined by serum reactivity to peptides. Competition enzyme-linked immunosorbent assays and neutralization assays were performed with domain II, III, or III plus Ib of PE38 and confirmed the immunodominance of domain III. To analyze the role of specific amino acids in antibody binding, individual amino acids of PE38 with large accessible surface areas were altered by site-directed mutagenesis. These results also show that the predicted areas of immunogenicity agree with the reactivity of the anti-PE38 antibodies to peptides and to the mutants of PE.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927788      PMCID: PMC303226          DOI: 10.1128/iai.62.11.5055-5065.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  30 in total

Review 1.  Recombinant toxins as novel therapeutic agents.

Authors:  I Pastan; V Chaudhary; D J FitzGerald
Journal:  Annu Rev Biochem       Date:  1992       Impact factor: 23.643

2.  Epitope mapping employing immobilized synthetic peptides. How specific is the reactivity of these peptides with antiserum raised against the parent protein?

Authors:  R Savoca; C Schwab; H R Bosshard
Journal:  J Immunol Methods       Date:  1991-08-09       Impact factor: 2.303

3.  Systematic fractionation of serum antibodies using multiple antigen homologous peptides as affinity ligands.

Authors:  G Tribbick; B Triantafyllou; R Lauricella; S J Rodda; T J Mason; H M Geysen
Journal:  J Immunol Methods       Date:  1991-06-03       Impact factor: 2.303

4.  Mapping antibody binding sites on cytochrome c with synthetic peptides: are results representative of the antigenic structure of proteins?

Authors:  C Schwab; A Twardek; T P Lo; G D Brayer; H R Bosshard
Journal:  Protein Sci       Date:  1993-02       Impact factor: 6.725

Review 5.  The use of immunotoxins for cancer therapy.

Authors:  L H Pai; I Pastan
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 6.  Humanized antibodies: enhancing therapeutic utility through antibody engineering.

Authors:  L K Jolliffe
Journal:  Int Rev Immunol       Date:  1993       Impact factor: 5.311

7.  Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer.

Authors:  K J Helzlsouer; G B Gordon; A J Alberg; T L Bush; G W Comstock
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

Review 8.  Immunotoxin therapy for cancer.

Authors:  L H Pai; I Pastan
Journal:  JAMA       Date:  1993-01-06       Impact factor: 157.335

9.  B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.

Authors:  U Brinkmann; L H Pai; D J FitzGerald; M Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 12.779

10.  Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.

Authors:  L H Pai; M A Bookman; R F Ozols; R C Young; J W Smith; D L Longo; B Gould; A Frankel; E F McClay; S Howell
Journal:  J Clin Oncol       Date:  1991-12       Impact factor: 50.717

View more
  10 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.

Authors:  Dmitrij Hristodorov; Radoslav Mladenov; Rainer Fischer; Stefan Barth; Theo Thepen
Journal:  Immunol Cell Biol       Date:  2016-01-08       Impact factor: 5.126

Review 3.  Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

Review 4.  Immunogenicity of therapeutic recombinant immunotoxins.

Authors:  Ronit Mazor; Masanori Onda; Ira Pastan
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 10.983

5.  Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.

Authors:  Ronit Mazor; Jaime A Eberle; Xiaobo Hu; Aaron N Vassall; Masanori Onda; Richard Beers; Elizabeth C Lee; Robert J Kreitman; Byungkook Lee; David Baker; Chris King; Raffit Hassan; Itai Benhar; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-05       Impact factor: 12.779

6.  Generation of neutralizing antipeptide antibodies to the enzymatic domain of Pseudomonas aeruginosa exotoxin A.

Authors:  H S Elzaim; A K Chopra; J W Peterson; R Goodheart; J P Heggers
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.609

Review 7.  Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.

Authors:  Yehudit Grinberg; Itai Benhar
Journal:  Biomedicines       Date:  2017-06-02

Review 8.  Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.

Authors:  Dmitrij Hristodorov; Radoslav Mladenov; Michael Huhn; Stefan Barth; Theo Thepen
Journal:  Toxins (Basel)       Date:  2012-09-14       Impact factor: 4.546

9.  Protection against exotoxin A (ETA) and Pseudomonas aeruginosa infection in mice with ETA-specific antipeptide antibodies.

Authors:  H S El-Zaim; A K Chopra; J W Peterson; M L Vasil; J P Heggers
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.609

Review 10.  Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation.

Authors:  Ronit Mazor; Ira Pastan
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 8.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.